Press "Enter" to skip to content

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co’s immunotherapy Keytruda and Pfizer Inc’s Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Also Read:   Indian pharmaceutical firms will play important role in fight against COVID19 pandemic: Ambassador Taranjit Singh Sandhu